Kimberly-Clark stock (US4943681035): EU clears major tissue business deal with Suzano

Kimberly-Clark's international tissue business sale to Suzano gains EU regulatory approval in a deal valued over $3 billion, marking a key strategic shift as the company focuses on core markets.

Kimberly-Clark has received EU regulatory clearance for its over $3 billion deal to sell its international tissue business to Suzano, advancing a major transaction first announced earlier. The approval, detailed in recent updates, clears a significant hurdle for the joint venture structure, allowing Kimberly-Clark to streamline operations outside North America. This development follows the company's strong Q1 earnings beat on April 28, 2026, where it reported EPS of $1.97 on revenue of $4.16 billion, surpassing estimates of $1.93 and $4.09 billion, respectively, according to MarketBeat as of 05/08/2026.

As of: 11.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Kimberly-Clark Corporation
• Sector/industry: Household & Personal Products
• Headquarters/country: United States
• Core markets: North America, global consumer goods
• Key revenue drivers: Personal care, consumer tissue, professional products
• Home exchange/listing venue: Nasdaq (KMB)
• Trading currency: USD

Kimberly-Clark: core business model

Kimberly-Clark Corporation manufactures and markets personal care products, consumer tissue, and professional products worldwide, with leading brands like Huggies, Kleenex, Kotex, and Depend. The company operates through three segments: Personal Care (diapers, training pants), Consumer Tissue (bathroom and facial tissues), and K-C Professional (wipers, safety products). This diversified portfolio serves essential daily needs, providing stability amid economic cycles. North America generates the bulk of sales, making it highly relevant for US investors tracking consumer staples resilience.

In recent quarters, the firm has emphasized organic growth and margin expansion through supply chain efficiencies and premiumization. Revenue for the trailing twelve months reached levels supporting a net margin of 12.80% and return on equity of 152.79%, as reported in Q1 2026 results published April 28, 2026, per MarketBeat as of 05/08/2026.

Main revenue and product drivers for Kimberly-Clark

Personal Care accounts for roughly half of sales, driven by diapers and incontinence products amid aging populations and steady birth rates in core markets. Consumer Tissue, now set for restructuring via the Suzano deal, contributes through high-volume essentials like Kleenex and Scott brands. K-C Professional taps into workplace hygiene demand, boosted post-pandemic. Q1 2026 revenue grew 2.7% year-over-year to $4.16 billion, reflecting pricing power and volume stability, according to earnings data from April 28, 2026, via MarketBeat as of 05/11/2026.

Kimberly-Clark tissue deal with Suzano gains EU approval

The European Commission cleared Suzano's acquisition of Kimberly-Clark's international tissue operations in a transaction valued over $3 billion, as updated recently. This joint venture will see Suzano take control outside North America, allowing Kimberly-Clark to exit non-core assets and focus on higher-margin segments. The deal, first revealed earlier, enhances Suzano's global footprint while providing Kimberly-Clark with capital for reinvestment, per MarketScreener as of recent update and Investing.com.

Closing at $98.31 on May 8, 2026, on Nasdaq, the stock reflects a year-to-date decline of 2.6% from $100.89, with a 52-week range of $92.42 to $144.30, according to MarketBeat as of 05/08/2026. This positions KMB as a defensive play for US portfolios amid consumer spending scrutiny.

Why Kimberly-Clark matters for US investors

Listed on Nasdaq as KMB, Kimberly-Clark derives over 40% of revenue from the US, exposing it directly to American consumer trends in essentials. Its scale in tissue and personal care offers dividend reliability, appealing to income-focused US investors. The Suzano deal could unlock value by concentrating on US-centric growth, enhancing relevance in portfolios seeking staples exposure.

Industry trends and competitive position

In the $200+ billion global hygiene market, Kimberly-Clark competes with Procter & Gamble and Essity, holding top positions in diapers and tissues. Trends like sustainability and e-commerce shift favor its innovation pipeline, including plant-based products. Post-deal, a leaner tissue footprint outside the US bolsters competitiveness in premium segments.

Conclusion

The EU clearance of the Suzano tissue deal represents a pivotal step for Kimberly-Clark, potentially freeing resources for core US operations amid solid Q1 results. With shares trading near $98 on Nasdaq and analysts eyeing $114.93 on average, the stock remains a staple in defensive strategies. Investors will watch execution of the transaction and upcoming quarters for sustained momentum.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.